Heterogeneity of Mycobacterium tuberculosis drug resistance in respect of pharmacokinetics of anti-tuberculosis drugs as a basis for individual treatment regimen

This article analyzes the ways of treatment efficacy enhancement in drug resistant tuberculosis patients through transfer to the individual treatment regimens basing on the objective laboratory data. The presence of M. tuberculosis population heterogeneity has been demonstrated as per the degree of resistance to different drugs relating individual pharmacokinetic features of the patients. The article includes discussion of technical opportunities for the implementation of such approach, the need for detail evaluation of the germ resistance and limits of effective action of anti-tuberculosis drugs related to their pharmacokinetics and pharmacogenetics.

tuberculosis, individual treatment regimens, drug resistance of M. tuberculosis, minimum inhibiting concentration of anti-tuberculosis drugs, acetylation types, pharmacokinetics, pharmacogenetics

1. Vasilyeva I.A., Aksenova V.A., Ergeshev A.E. et al. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple drug resistance]. Tver, OOO Izdatelstvo Triada Publ., Issue 2, 2014, 72 p.

2. Kasayeva T.Ch., Sterlikov S.A. Son I.M. et al. Otraslevye i ekonomicheskye pokazateli protivotuberkuleznoy raboty v 2012-2013 gg. Analitichesky obzor osnovnykh pokazateley i statisticheskiye materialy. [Economic rates for TB control in 2012-2013. Analysis of main rates and statistic materials.] Moscow, OOO Kolor Media Publ., 2014, 71 p.

3. Kibrik B.S., Melnikov V.P., Makovey Yu.V. Specifics of diagnosis and progression of disseminated pulmonary tuberculosis. Probl. Tub., 2008, no. 8, pp. 3-5. (In Russ.)

4. Markelov Yu.M. Specifics of multiple drug resistant tuberculosis and priority actions to limit its transmission in Karelia. Vestn. Sovr. Klin. Med., 2011, vol. 4, no. 3, pp. 50-56. (In Russ.)

5. Mutaykhan J. Perenosimost protivotuberkuleznykh preratov i individualnye kharakteristiki ikh metabolisma u bolnykh tuberkulezom legkikh s latentno protekayuschimi khronicheskimi virusnymi gepatitami i zabolevaniyami pischevaritelnogo trakta. Diss. kand. med. nauk. [Tolerance of TB drugs and individual parameters of their metabolism in pulmonary tuberculosis patients with latent hepatitis viruses and digestive system disorders. Cand. Diss.]. Novosibirsk, 2007, 150 p. (in Russ.)

6. Popov S.A., Puzanov V.A., Rusch-Gerdes S. et al. Systema MGIT dlya kulturalnoy diagnostiki i opredeleniya lekarstvennoy chuvstvitelnosti mikobakteriy tuberkuleza. Standartnye operatsionnye protsedury. [MGITfor culture diagnostics and drug susceptibility testing of tuberculosis mycobacteria. Standard operation procedures.] Moscow, BD 2007, 24 p.

7. Edict no. 109 by RF MoH as of 21.03.2003 On Improvement of TB Control Measures in the Russian Federation. Moscow, MZ RF Publ., 2003, 347 p.

8. Edict no. 951 by RF MoH as of 29.19.2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics and Treatment. Moscow, MZ RF Publ., 2014, 42 p.

9. Registr lekarstvennykh stredstv Rossii. Entsiklopedia lekarstv. [Russian register of medications. Encyclopedia of drugs.] Edited by Vyshkovsky G.L., Moscow, RLS-2007 Publ., 2007, 1503 p.http://www.rlsnet.ru/mnn_index_id_627.htm. 03.02.2015

10. Chubaryan V.T. Ispolzovaniye osobennostey farmakokinetiki protivotuberkuleznykh preparatov s tselyu optimizatsii kombinirovannoy terapii bolnykh tuberkulezom legkikh. Diss. dokt. med. nauk.[Application of pharmacokinetic features of anti-tuberculosis drug in order to optimize combined therapy of pulmonary tuberculosis patients. Doct. Diss.] Volgograd, 2008, 180 p. (in Russ.)

11. BD Bactec MGIT 960 SIRE kits for the antimycobacterial susceptibility testing of Micobacterium tuberculosis: USAMD.: Becton, Dickinson and Company. 2010, 73 p.

12. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 1998, vol. 26. pp. 1-12.

13. Berode M., Savolainen H. Occupational exposure to isocyanates and individual susceptibility. Soz Praventivmed. 1993, vol. 38, suppl. 2. pp. 125-S127.

14. European Committee on Antimicrobial Susceptibility Testing. Version 1.3:EUCAST, 2011. 2011, 68 p.

15. Global tuberculosis report 2014. WHO. [Online]. 2014, URL: http://www.who.int/tb/publications/global_report/en/(accessed 12.11.2014)

16. Guengerich F.P. Cytochrome P450: what have we learned and what are the future issues? Drug. Metab. Rev. 2004, vol. 36, no. 2, pp. 159-197.

17. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update, WHO, Geneva. 2011, 44 p.

18. Jenkins H.E., Crudu V., Soltan V. et al. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. Eur. Respir. J., 2014, vol. 43, no. 4, pp. 1132-1141.

19. Johnson J. Pharmacogenetics: Potential for individualized drug therapy through genetics. Trends in Genetics. 2003, vol. 19, no. 11, pp. 660-666.

20. Katiyar S.K. et al. A Randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung. Dis., 2008, vol. 12, no. 2, pp. 139-145.

21. Kinzig-Schippers M., Tomalik-Scharte D., Jetter A. et al. Should we use Nacetyltransferase type 2 genotyping to personalize doses? Antimicrob. Agents Chemother., 2005, vol. 49, no. 5, pp. 1733-1738.

22. Peloquin C.A., Jaresko G.S., Yong C.L. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 1997, vol. 41, no. 12, pp. 2670-2679.

23. Rao K.V., Mitchison D.A., Nair N.G. et al. Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br. Med J., 1970, vol. 3(5721), pp. 495-497.

24. Rey E., Gendrel D., Treluyer J.M. et al. Isoniazid pharmacokinetics in children according toacetylator phenotype. Sci. Fundamental & Clinical Pharmacology, 2001, vol. 15. pp. 355-359.

25. Vatsis K. P., Martell K. J., Weber W. W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci., USA, 1991, vol. 88, no. 14, pp. 333-337.

26. Vavilin V.A. Makarova S.I., Kolpakova T.A. et al. The prognostic value of genetic and phenotypic markers of drug metabolism and host and exposure factors for antituberculous drug-induced hepatotoxicity. EhrlichII, 2nd World Conference on Magic Bullets, Nurnberg, October 2-5, 2008.

27. Woods G.L., Brown-Elliott B.A., Conville P.S. et al. Susceptibility testing of Micobacteria, Nocardiae, and other aerobic Actinomycetes; Approved standard, second edition: USA. NCLSI. 2011, M24-A2, vol, 31, no. 5, 63 p.